Precision medicine has transformed the approach to cancer. It promotes the use of increasingly sensitive molecular tools to characterize disease, monitor progression and support clinical decision-making.<\/p>\n\n\n\n
In this context<\/strong>, the integration of liquid biopsy, pathology and oncohematology<\/strong> represents a key advance. This approach can improve molecular stratification, therapeutic monitoring and early detection of relapse.<\/p>\n\n\n\n Liquid biopsy<\/strong> has become a minimally invasive method for analyzing circulating biomarkers. These biomarkers include circulating tumor DNA, also known as ctDNA<\/strong>, circulating free RNA, circulating tumor cells and other biological fractions of interest.<\/p>\n\n\n\n Moreover<\/strong>, liquid biopsy makes it possible to obtain molecular information over time. This information is dynamic and may reflect tumor heterogeneity more accurately than a single tissue sample.<\/p>\n\n\n\n Its most relevant clinical and translational applications include the identification of actionable molecular alterations, treatment response monitoring and detection of resistance mechanisms. It can also support residual disease assessment and longitudinal follow-up in solid tumors and hematological malignancies.<\/p>\n\n\n\n However<\/strong>, results must always be interpreted in the right clinical context. Sample type, tumor burden, genetic material fragmentation and assay sensitivity can all influence diagnostic performance.<\/p>\n\n\n\n Among emerging molecular methodologies, digital PCR<\/strong>, or dPCR<\/strong>, has become a valuable tool for molecular analysis. It is especially useful when the tumor fraction is low or when the available material is limited.<\/p>\n\n\n\n dPCR is based on the partitioning of a sample into many individual reactions. As a result<\/strong>, it enables absolute quantification<\/strong> without the need for standard curves.<\/p>\n\n\n\n This feature improves the detection of variants with low allele frequency. In addition<\/strong>, it provides high sensitivity, specificity, reproducibility and quantitative accuracy.<\/p>\n\n\n\n In the field of liquid biopsy, dPCR is particularly useful for ctDNA analysis. This material is often present in low quantities and is highly fragmented.<\/p>\n\n\n\n Therefore<\/strong>, dPCR can support the detection of low-abundance mutations and the precise quantification of somatic variants. It can also help monitor molecular burden over time and assess residual disease or molecular relapse.<\/p>\n\n\n\n Pathology remains an essential discipline in cancer diagnosis. Traditionally, it has relied on histomorphological evaluation of tissue samples.<\/p>\n\n\n\n Today<\/strong>, this evaluation is increasingly complemented by techniques such as immunohistochemistry, in situ hybridization and molecular studies. Together, these methods create a more complete and clinically informative diagnostic model.<\/p>\n\n\n\n This integrated approach helps refine diagnostic classification. Furthermore<\/strong>, it can establish correlations between tumor morphology and molecular profile.<\/p>\n\n\n\n It also supports the identification of prognostic and predictive biomarkers. These biomarkers can be relevant for treatment selection and patient stratification.<\/p>\n\n\n\n In this setting, dPCR provides additional value when working with complex or limited samples. These may include FFPE tissues, cytological material or small biopsies.<\/p>\n\n\n\n For this reason<\/strong>, dPCR can help maximize the molecular information obtained from challenging samples. It can also improve the reproducibility of targeted assays and complement histological findings with precise quantitative data.<\/p>\n\n\n\n In oncohematology<\/strong>, high-sensitivity molecular techniques have expanded the ability to detect clonal alterations. They also support the quantification of molecular burden and the monitoring of residual disease.<\/p>\n\n\n\n Biomarker analysis can be performed in peripheral blood, bone marrow or plasma. In addition<\/strong>, it can complement morphological and immunophenotypic information with molecular data of high clinical value.<\/p>\n\n\n\n dPCR is especially relevant in this field. It can detect minor clones, quantify somatic mutations and support accurate monitoring of measurable residual disease.<\/p>\n\n\n\n Moreover<\/strong>, it may contribute to the early identification of molecular persistence, progression or relapse. This can help develop more personalized monitoring strategies.<\/p>\n\n\n\n The ability to obtain absolute and reproducible quantitative results reinforces the role of dPCR in oncohematology. Overall<\/strong>, it supports more precise diagnosis and follow-up of hematological malignancies.<\/p>\n\n\n\n The convergence of diagnostic disciplines and advanced molecular technologies is redefining the role of the laboratory in oncology.<\/p>\n\n\n\n The combination of liquid biopsy, pathology, oncohematology and dPCR<\/strong> provides complementary information. This information can help characterize disease, monitor its evolution and support clinical decisions.<\/p>\n\n\n\n As a result<\/strong>, diagnostic integration is no longer only a future perspective. It is becoming a present need in the modern management of cancer patients.<\/p>\n\n\n\n Reliable, reproducible and clinically interpretable analytical results are essential in this new paradigm. They help translate molecular knowledge into a more precise and personalized clinical practice.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" An integrated approach to improving molecular characterization, disease monitoring and clinical decision-making in oncology. Precision medicine has transformed the approach to cancer. It promotes the use of increasingly sensitive molecular tools to characterize disease, monitor progression and support clinical decision-making. In this context, the integration of liquid biopsy, pathology and oncohematology represents a key advance. …<\/p>\n","protected":false},"author":13,"featured_media":3444,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[35,37],"tags":[],"class_list":["post-3443","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopsy","category-genetics"],"acf":[],"yoast_head":"\ndPCR: a key technology for high-sensitivity molecular analysis<\/strong><\/h4>\n\n\n\n
Pathology and molecular diagnosis: a necessary integration<\/strong><\/h4>\n\n\n\n
Liquid biopsy in oncohematology: clinical applications of dPCR<\/strong><\/h4>\n\n\n\n
Towards a more integrated and precise cancer diagnosis<\/strong><\/h4>\n\n\n\n
<\/h2>\n\n\n\n